Literature DB >> 8992519

[Bradycardia after beginning therapy with metoprolol and paroxetine].

F König1, M Häfele, B Hauger, M Löble, S Wössner, M Wolfersdorf.   

Abstract

Because of their low incidence of adverse effects SSRI are prescribed more and more frequently in patients with depressive disorders. SSRI inhibit different subsystems of cytochrome-P 450-oxydase. Especially during co-administration of SSRI with antipsychotic and antiarrhythmic drugs pharmacokinetic interactions have to be observed carefully. In this presentation a case of bradycardia after co-administration of paroxetine and metoprolol is reported. Drug history and a careful drug monitoring are necessary requirements to avoid serious adverse effects.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8992519

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN： 0303-4259


  6 in total

1.  Dose-dependent bradycardia with citalopram in an elderly patient.

Authors:  Kalpana P Padala; Prasad R Padala; Steven P Wengel
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

3.  Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.

Authors:  Muh Akbar Bahar; Yuanyuan Wang; Jens H J Bos; Bob Wilffert; Eelko Hak
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-03-24       Impact factor: 2.890

4.  Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.

Authors:  Muh Akbar Bahar; Jens H J Bos; Sander D Borgsteede; Aafje Dotinga; Rolinde A Alingh; Bob Wilffert; Eelko Hak
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

5.  Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.

Authors:  Ane Gedde-Dahl; Olav Spigset; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2022-07-25       Impact factor: 3.064

6.  The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.

Authors:  Muh Akbar Bahar; Jasper Kamp; Sander D Borgsteede; Eelko Hak; Bob Wilffert
Journal:  Br J Clin Pharmacol       Date:  2018-09-24       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.